Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17782306 | 1.00 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL17782275 | 0.98 | MEN1 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL1117897 | 0.94 | CHRNB2 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL1778807 | 0.94 | CHRNB2 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL1780308 | 0.94 | CHRNB2 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL17437260 | 0.92 | CHRNB2 (0.49) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL15300656 | 0.92 | CHRNB2 (0.49) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL15300655 | 0.90 | CHRNB2 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL14881196 | 0.83 | MAPT (0.48) | CYP2C19CHRNB2CHRNA4SMN1; SMN2CYP2A6 | |
| Hydrochloric Acid SCHEMBL15301821 | 0.81 | MAPT (0.47) | CYP2C19CHRNB2CHRNA4SMN1; SMN2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025077856-A1 | TRICYCLIC-CARBONYL-NITROGEN HETEROCYCLIC DERIVATIVES AND USE THEREOF | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2025-04-17 | — | — | WO | disclosed |
| CN-119219649-A | Complement factor B inhibitor, pharmaceutical composition, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-118108700-A | Complement factor B inhibitor, pharmaceutical composition, preparation method and application thereof | 诺华股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4282486-A2 | COMPLEMENT FACTOR B INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| US-20230286947-A1 | COMPLEMENT FACTOR B INHIBITOR, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| EP-4194451-A1 | COMPLEMENT FACTOR B INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022226667-A1 | SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| CN-114057758-A | Complement factor B inhibitor and pharmaceutical composition, preparation method and application thereof | 上海美悦生物科技发展有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-9682968-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2016-06-02 | — | — | US | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| CN-102753538-A | Sultam derivatives | HOFFMANN LA ROCHE | 2012-10-24 | — | — | CN | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
| CN-1087083-A | The intermediates preparation of synthetic 3-amino piperidine derivatives | PFIZER (US) | 1994-05-25 | — | — | CN | disclosed |
| CN-1053060-A | 3-aminopiperidine derivatives and related nitrogen-containing heterocycles | PFIZER (US) | 1991-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, TFPI, TFPI2 | MEN1 861/4885CYP2D6 1474/4885CYP2C19 234/4885 |
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | MEN1 2017/4885CYP2D6 2555/4885CYP2C19 1931/4885 |
| US-20110124686-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, SULT1E1 | MEN1 3823/4885CYP2D6 65/4885CYP2C19 183/4885 |
| US-20230286947-A1 | COMPLEMENT FACTOR B INHIBITOR, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF | CFB, TFPI, CFH | MEN1 587/4885CYP2D6 1922/4885CYP2C19 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.